A reminder that it's hard to change the perverse incentives in the drug value chain.
read full article ›This article highlights the commercial challenges facing gene therapies and flicks at a couple of important points that are worth further exploration.
read full article ›For those interested in how biotech and pharma companies communicate about drug value, patient access, and pricing philosophies, corporate responsibility reports are required reading. Many times these reports appear transparent, but aren't given information is averaged across the entire portfolio.
read full article ›Today’s WSJ article on copay alternate funding models (AFM) is the latest in a series of stories in the mainstream media about a game of chicken between drugmakers and payers. It's sure to be a hot topic at #Asembia23, the annual confab happening now in Las Vegas focused on all things specialty drug related.
read full article ›Pharma peeps: is medication co-pay affordability specifically for your Medicare patients a top concern? @Real Endpoints has developed an AI-based tool that might be of interest. Watch the video for more information and reach out to Susan Raiola, Julia Murphy, or Denise Wolff, Pharm D for more.
read full article ›With the news that Giovanni Caforio is handing the baton to Chris Boerner, I think we can say we called this one right. In all seriousness, it's no surprise to us that companies recognize the importance of putting people with deep market access roots into leadership positions. The commercial landscape is only growing more complex.
read full article ›